DUO/AMP-LST: Endoscopic Characteristics of Duodenal and Ampullary Lesions

Sponsor
Professor Michael Bourke (Other)
Overall Status
Recruiting
CT.gov ID
NCT01556399
Collaborator
(none)
350
1
120
2.9

Study Details

Study Description

Brief Summary

The purpose is to investigate whether polyps that look different at endoscopy, have formed via different mutations and have different risks of turning into cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: Tissue Sampling

Detailed Description

Laterally spreading tumours (LSTs), are polyps that have a lateral extension along the duodenal wall with minimal vertical growth. It has become evident over the last few years that rather than being a single entity requiring an accumulation of mutations, Duodenal and ampullary cancer is in fact a heterogenous disease forming via multiple distinct genetic pathways. It is therefore hypothesised that different polyp types have different genetic abnormalities, and potentially form via distinct genetic pathways, although this theory has not been widely examined.

This knowledge would be important in furthering our understanding of the development of cancer. There is accumulating evidence that genetic abnormalities may be a better predictor of cancer behaviour than histological grade. Additionally, guidelines for endoscopy surveillance are currently a one size fits all approach that do not reflect the genetic heterogeneity of the disease and the knowledge that only 5% of polyps progress to cancer. Genetic studies may assess future cancer risk to a person in polyps once removed and plan surveillance endoscopy frequency.

Study Design

Study Type:
Observational
Anticipated Enrollment :
350 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
A Correlation of the Endoscopic Characteristics of Duodenal and Ampullary Laterally Spreading Tumours With Their Somatic or Germline Mutations.
Study Start Date :
Nov 1, 2011
Anticipated Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Duodenal adenomas

Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.

Other: Tissue Sampling
A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.

Outcome Measures

Primary Outcome Measures

  1. Significant differences in molecular abnormalities. [Specimens will be stored and used for up to 15 years]

    The aim of this project is to look for statistically significant differences in molecular abnormalities from the three known genetic pathways, between the two different morphological types, granular and non-granular, to potentially demonstrate that these different polyps form via different genetic pathways.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Intention to perform Endoscopic Mucosal Resection

  • Adenoma equal to or greater than 20mm

  • over 18 years of age

  • Able to give informed consent to involvement in trial

Exclusion Criteria:
  • Pregnancy

  • Lactation: currently breastfeeding

  • Taken clopidogrel within 7 days

  • Taken warfarin within 5 days

  • Had full therapeutic dose unfractionated heparin within 6 hours

  • Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours

  • Known clotting disorder

Contacts and Locations

Locations

Site City State Country Postal Code
1 Westmead Hospital Westmead New South Wales Australia 2145

Sponsors and Collaborators

  • Professor Michael Bourke

Investigators

  • Principal Investigator: Michael Bourke, MBBS, FRACP, Western Sydney Local Health District

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Professor Michael Bourke, Director of Gastrointestinal Endoscopy, Western Sydney Local Health District
ClinicalTrials.gov Identifier:
NCT01556399
Other Study ID Numbers:
  • LST-UGIM
First Posted:
Mar 16, 2012
Last Update Posted:
Mar 23, 2021
Last Verified:
Mar 1, 2021
Keywords provided by Professor Michael Bourke, Director of Gastrointestinal Endoscopy, Western Sydney Local Health District
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 23, 2021